Abstract RAS (KRAS, NRAS and HRAS) is the most frequently mutated gene family in
cancers, and, consequently, investigators have sought an effective RAS inhibitor for more …

The mitogen-activated protein kinase (MAPK) pathway is an important bridge in the switch
from extracellular signals to intracellular responses. Alterations of signaling cascades are …

PURPOSE To provide evidence-based recommendations updating the 2017 ASCO
guideline on systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC) …

Context.—In 2013, an evidence-based guideline was published by the College of American
Pathologists, the International Association for the Study of Lung Cancer, and the Association …

RAS is the most frequently mutated oncogene in human cancers, with mutations in about
30% of all cancers. RAS exists in three different isoforms (K-RAS, H-RAS and N-RAS) with …

BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway.
Concomitant mutations in both KRAS and BRAF genes have been identified in non-small …

Lung neoplasms are the leading cause of death by cancer worldwide. Non-small cell lung
cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of …

KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer
(NSCLC). It was previously thought to be an" undruggable" target due to the lack of deep …

In patients with non-small cell lung cancer (NSCLC), the most frequent oncogene driver
mutation in Western countries is Kirsten rat sarcoma viral oncogene homolog (KRAS), and …

Importance There are no specifically approved targeted therapies for the most common
genomically defined subset of non–small cell lung cancer (NSCLC), KRAS-mutant lung …